Showing 3511-3520 of 5956 results for "".
- Ophthalmic Societies Call on FDA to Keep Moxifloxacin on Bulk Substance Listhttps://modernod.com/news/ophthalmic-societies-call-on-fda-to-keep-moxifloxacin-on-bulk-substance-list/2478293/Several ophthalmic organizations have collectively sent a letter to the FDA requesting that the agency retain moxifloxacin as Category 1 for outsourcing facility use (503b), citing a demonstrated clinical need for the medication as a bulk substance. The request comes after the FDA, on July 31, ga
- MetLife to Acquire Versant Health, Owner of Davis Vision and Superior Visionhttps://modernod.com/news/metlife-to-acquire-versant-health-owner-of-davis-vision-and-superior-vision/2478292/MetLife announced it has entered into a definitive agreement to acquire Versant Health from an investor group led by Centerbridge Partners and including FFL Partners for approximately $1.675 billion in an all-cash transaction. Versant Health owns the marketplace brands Davis Vision and Superior V
- Zeiss Launches New Frame and Lens Disinfecting Technology to Support Safety and Hygiene in Eye Care Practiceshttps://modernod.com/news/zeiss-launches-new-frame-and-lens-disinfecting-technology-to-support-safety-hygiene-and-productivity-in-eyecare-practices/2478262/Zeiss Vision Care US announced the launch of the
- Orbis International Announces New CEO & Presidenthttps://modernod.com/news/orbis-international-announces-new-ceo-president/2478251/Orbis International announced the appointment of Derek Hodkey as the organization’s new CEO and President, with immediate effect, following the retirement of Bob Ranck, who led Orbis for over 4 years.
- COVID-19 Vaccine Developers Seek to Reassure Public Over Safetyhttps://modernod.com/news/covid-19-vaccine-developers-seek-to-reassure-public-over-safety/2478249/Sources suggested that a number of drugmakers, including GlaxoSmithKline, Johnson & Johnson and Pfizer, are planning to release a statement outlining their commitment to only seek FDA approval of a vaccine against COVID-19 if it is supported by extensive safety and efficacy data. The move is
- Saliva COVID-19 Test as Good as, Perhaps Beats, Nasal Swab: Studyhttps://modernod.com/news/saliva-covid-19-test-as-good-as-perhaps-beats-nasal-swab-study/2478248/A COVID-19 saliva test protocol developed by researchers at Yale University appeared to perform at least as well as nasal swabs in a study of hospital patients, a finding that may help encourage more frequent use of self-collected samples, according to a Medscape
- Analysis Finds Corticosteroids Cut Risk of Death in Critically Ill COVID-19 Patientshttps://modernod.com/news/analysis-finds-corticosteroids-cut-risk-of-death-in-critically-ill-covid-19-patients/2478240/Results of a meta-analysis published Wednesday in JAMA suggest that the use of systemic corticosteroids in critically ill patients with COVID-19 is associated with lower 28-day all-cause mortality compared to usual care or placebo. Study author Jonathan Sterne noted that the benefit was
- Pandemic Will Leave Children With Less Access to Eye Care, New Survey Showshttps://modernod.com/news/pandemic-will-leave-children-with-less-access-to-eye-care-new-survey-shows/2478227/A survey conducted by the American Association for Pediatric Ophthalmology and Strabismus (AAPOS) shows that pediatric specialists are struggling to keep their practices viable in the wake of the shutdown. As a result, ch
- Amazon Enters Health-Tracking Space With Halo Wristband, App Debuthttps://modernod.com/news/amazon-enters-health-tracking-space-with-halo-wristband-app-debut/2478213/Amazon introduced Halo on Thursday, a subscription service that uses an app and wristband to monitor an individual’s overall health and wellness, including activity, sleep and body fat, as well as tone of voice to analyze emotional well-being. “We are using Amazo
- AGTC Announces Publication of Preclinical Data that Support the Ongoing Clinical Development of Its XLRP Gene Therapy Programhttps://modernod.com/news/agtc-announces-publication-of-preclinical-data-that-support-the-ongoing-clinical-development-of-its-xlrp-gene-therapy-program/2478200/Applied Genetic Technologies Corporation (AGTC) announced that preclinical data validating the transgene (hRPGRco) that is being evaluated in the company’s ongoing phase 1/2 clinical trial in patients with X-lined retinitis pigmentosa (XLRP) have been published in the July 15, 2020 print issue of